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In light of the fifth annual International Fluid Academy Days (IFAD) meeting in Antwerp, Belgium, it is time to reflect on the years that have passed since the first IFAD meeting and the publication of the major fluid trials in high profile journals [1] [2] [3] [4] [5] [6] . While these produced partly conflicting results, some contained signals of increased mortality and higher incidence of renal replacement therapy associated with the administration of hydroxyethyl starch (HES). This led to warnings by regulatory bodies and virtually imposed a clinical ban on artificial colloids [7] . Incidentally, this also triggered the great fluid debate [8] and arguably fueled the success of IFAD [9] .
Many clinicians judged the ban on HES to be premature. It was suggested that the baby would be thrown out with the bathwater, and therefore the studies were extensively and vividly debated on, often becoming a matter of belief vs. evidence [10, 11] . Specific concerns included the amount and type of fluid patients had received before randomization, and the unspecified criteria for starting renal replacement therapy.
While it is not our aim to reiterate these concerns, the review by Dr. Hahn in this issue of Anaesthesiology Intensive Therapy [12] reminds us of the ongoing debate and specifically of the importance of attention to detail. The review discusses the commonly held opinion that hypervolemia should be avoided. This opinion is supported by studies showing the release of atrial natriuretric peptide in response to hypervolemia, which is associated with glycocalyx shedding. The latter could lead to extravasation of proteins and fluids, which seemed to be confirmed by the report that hydroxyethyl starch, only expands the plasma by 40% of the infused volume in conditions of hypervolemia. Dr Hahn challenges these and other studies by critically disputing the validity of the methods used.
Dr. Hahn's meticulous explorations remind us of the importance of a thorough understanding of physiology by both scientists and intensivists. In fact, the practice of intensive care medicine may be viewed as applied physiology at the bedside. Interestingly, a perceived lack of physiologic rationale for fluid therapy was one of the main criticisms of the major fluid trials. As expressed in a commentary [13] , "physiology teaches us that it is essential to define a clear hemodynamic endpoint in the individual administration of any solution. Thus, while the trials were impressive, it is unclear if fluids were used correctly".
In general, accepted therapeutic principles must be followed. These include avoidance of fluid overload. At times, no fluid administration will be better than non-indicated administration of whatever type of fluid. Hypervolemia, in the setting of a capillary leak, will lead to extravascular fluid accumulation, possibly causing organ edema, organ failure, and increasing morbidity and mortality. Appropriately defined treatment targets that are continuously being adjusted to the varying phases of critical illness will help one to reduce the risk of such complications.
The importance of attention to detail is exemplified by the fact that commentaries in scientific journals and lectures at scientific meetings dealing with the major fluid trials often cite information only contained in the appendices of the original publications. Given the frequent emotional nature of the [14] method on the two highly cited 6S [2] and Chest [1] trials on fluid therapy in critically ill patients. Our analysis shows that going over all PICO criteria, the main text of both publications provide insufficient information (Table 1) . This may well be clinically relevant.
There is a well-recognized trend in science to present information in an easily comprehensible albeit superficial space after fashion [15] . Busy clinicians, let alone regulatory bodies, are usually not inclined to routinely consult the appendices. If, however, clinically relevant information is contained within them, faulty conclusions and decision making may result. We therefore feel that all clinically relevant information must be contained in the main texts of publications.
The fluid debate provides important lessons in physiology, methodology and appendicitis. Surely, signals of potentially adverse effects of HES generated by the large fluid trials must not be ignored. However, they need to be interpreted in the context of trial-specific patient selection and of the timing and dosing of fluids.
We can possibly learn from other areas of medicine. For example, last year's publication in the New England Journal of Medicine of the MR. CLEAN trial [16] showed the benefit of intra-arterial treatment of stroke despite earlier negative trials. The neurology community succeeded in delineating a group of patients which benefits from a treatment that had previously failed under different circumstances. This re-emphasizes the utmost importance of patient selection, timing of intervention, and dosing of medication (and thus, also fluids) in affecting outcome.
In the context of fluid therapy in critically ill patients, the critical care community is well advised to follow this example. Considering patient safety and the financial implications of therapy with artificial colloids, the burden of proof of possible benefit of such treatment lies with the manufacturers and should only be pursued within the context of controlled clinical trials. Circulatory variables at 24h after randomization CVP 11 and 10 mm Hg, respectively; ScvO2 75 and 73%, respectively; serum lactate 2.0 mmol L -1 , respectively.
Heart rate 87 bpm, respectively; mean arterial pressure 81 mm Hg, respectively; CVP approx. 10.5 and 11.5, respectively; serum lactate approx. 1.5 mmol L -1 , respectively
